Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H1 2016', provides in depth analysis on P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted pipeline therapeutics. The report provides comprehensive information on the P2X Purinoceptor 7 (P2Z Receptor or P2RX7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - The report reviews P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics and enlists all their major and minor projects - The report assesses P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 7 (P2Z Receptor or P2RX7) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Overview 7 Therapeutics Development 8 P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Products under Development by Stage of Development 8 P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Products under Development by Therapy Area 9 P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Products under Development by Indication 10 P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Products under Development by Companies 14 P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Companies Involved in Therapeutics Development 22 Affectis Pharmaceuticals AG 22 Axxam SpA 23 Biosceptre (Aust) Pty Ltd 24 Evotec AG 25 Johnson & Johnson 26 Medestea Research & Production S.p.A. 27 P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Drug Profiles 28 AFC-5128 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 BIL-010t - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 BIL-011t - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 BIL-03n - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 BIL-03s - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 BIL-04s - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 BIL-06v - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 BIL-07v - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 EVT-401 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 JNJ-47965567 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 MED-1101 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Small Molecule to Antagonize P2X7 Receptor for Central Nervous System - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecules to Antagonize P2RX7 for CNS Disorders and Autoimmune Disorders - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Dormant Projects 41 P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Discontinued Products 42 P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Featured News & Press Releases 43 Dec 18, 2014: Alzheimer's Drug Discovery Foundation And Axxam Continue Their Successful Collaboration To Develop Novel Therapeutics For Alzheimer's Disease 43 Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma 43 Jan 25, 2012: Affectis Receives European Patent For AFC-5128 And Other P2X7 Antagonists 44 Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT 401 44 Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Early Stage Products, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Products under Development by Companies, H1 2016 15 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 21 Pipeline by Affectis Pharmaceuticals AG, H1 2016 22 Pipeline by Axxam SpA, H1 2016 23 Pipeline by Biosceptre (Aust) Pty Ltd, H1 2016 24 Pipeline by Evotec AG, H1 2016 25 Pipeline by Johnson & Johnson, H1 2016 26 Pipeline by Medestea Research & Production S.p.A., H1 2016 27 Dormant Projects, H1 2016 41 Discontinued Products, H1 2016 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
